Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study

Read full text Summarise with VIRAT
Authors: Giovanni Trovato, Martina Carullo, Antonella Nicastro, Chiara Spoto, E. Perissinotto, G. Giordano, Emanuela Di Giacomo, Maria Alessandra Calegari, Valentino Pasquinucci, Teresa Troiani, Stefano Tamberi, Marta Schirripa
+14 more M. Scartozzi, Federica Morano, Giulia Arrivi, Cristina Morelli, M. Basso, Matteo Landi, E. Martinelli, Federica Zoratto, Francesca Bergamo, Matteo Landriscina, Jessica Lucchetti, Chiara Cremolini, G. Tortora, Lisa Salvatore
Cited by: 0
References: 28

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: The SUNLIGHT trial established trifluridine/tipiracil (FTD/TPI) plus bevacizumab as a new later-line standard in metastatic colorectal cancer (mCRC). However, evidence in real-world populations-often older and more heterogeneous-remains limited. This study evaluated the effectiveness and safety of FTD/TPI plus bevacizumab in a large, unselected real-world mCRC population and aimed to identify potential predictive factors associated with response to this treatment. Patients and methods: We conducted a retrospective, multicenter analysis of patients with refractory mCRC treated with FTD/TPI plus bevacizumab across 15 Italian centers. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), overall response rate (ORR), and safety. Results: 297 patients were included. Median age was 61.8 years, and 79.1% had ≥2 metastatic sites. Most patients (89.9%) had prior bevacizumab exposure, and 35.4% had received ≥3 treatment lines. ORR was 7.4%, and the disease control rate was 54.2%. Median PFS was 5.3 months [95% confidence interval (CI) 4.5-6.5 months], and median OS was 11.9 months (95% CI 10.5-14.3 months). Eastern Cooperative Oncology Group performance status, tumor sidedness, metastatic burden, and time from metastatic diagnosis to treatment initiation results were statistically associated with OS. Any grade adverse events occurred in 243 (81.8%) patients, and grade 3-4 events in 152 (52.2%); grade 3-4 neutropenia was the most frequent and emerged in 35.4% of patients, while non-hematologic toxicities were mostly low grade. Conclusions: In this unselected real-world population, FTD/TPI plus bevacizumab demonstrated clinically meaningful activity and a tolerable safety profile. Outcomes were consistent with the SUNLIGHT trial, supporting the routine use of this combination in later-line option in mCRC.

Fields of Study & Subjects

Colorectal Cancer Treatments and Studies Intraperitoneal and Appendiceal Malignancies Colorectal Cancer Surgical Treatments

Publication details

Journal / source
ESMO Gastrointestinal Oncology
Volume
12
Pages
100317–100317
Publication date
19 March 2026
Language
EN